RALEIGH, N.C. (Aug. 30, 2012) – Bailey’s Fine Jewelry will become an official sports sponsor of the 2012-2013 Tar Heels and Wolfpack which means the familiar Bailey Box will become even better known in both schools’ football stadiums.
Fans from North Carolina State University and the University of North Carolina at Chapel Hill have plenty to look forward to on Saturdays. Game day highlights include a Bailey Box video board game at Carter-Finley Stadium, video board features and replays throughout the season at Kenan Stadium, private shopping events for each fan base and the popular Digging for Diamonds contest event at both schools.
Digging for Diamonds pits competing couples against each other in the on-field search for a $10,000 diamond ring hidden among many Bailey Boxes. The couple that finds the ring first leaves the home field victorious and with a new diamond ring. Digging for Diamonds will take place at both schools on Nov. 24 as the Tar Heels take on the Maryland Terrapins and the Wolfpack host Boston College.
“As a North Carolina born-and-bred company, we know the important role college sports play in the lives of our patrons,” said Trey Bailey, director of operations at Bailey’s Fine Jewelry. “It’s part of the culture here and we are so excited to be a new part of Tar Heel and Wolfpack fans’ game day experience.”
Established in 1948 in Rocky Mount, Bailey’s is a family-owned-and-operated business now under third-generation North Carolina leadership.
About Bailey’s Fine Jewelry
Bailey’s Fine Jewelry is a family owned-and-operated company with stores in Raleigh, Rocky Mount, Greenville and Fayetteville. Bailey’s offers jewelry from today’s most esteemed designers, exquisite diamonds, estate jewelry, fashion accessories, fine timepieces and gifts. With an emphasis on customer satisfaction, personalized services include custom design, watch and jewelry repair, appraisal and bridal registry. Steeped in family tradition, Bailey’s is one of the most well-regarded and innovative jewelry stores in North Carolina and is best known for its distinctive ‘Bailey Box’ slogan. For more information, please call toll-free (866) 725 – 3111 or visit online at www.baileybox.com.
August 30, 2012
August 20, 2012
SCYNEXIS to Present on Screening Technology Used in Anti-Malarial Research at ACS National Meeting
RESEARCH TRIANGLE PARK, N.C. (Aug. 20, 2012) – SCYNEXIS, Inc. announces the presentation of innovative screening approaches used in the discovery of promising anti-malarial therapies at the American Chemical Society’s (ACS) national meeting.
Paul J. Kowalczyk, Ph.D., senior computational chemist in the company’s Integrated Parasitology division, will make the presentation entitled, “Machine learning: Better practices applied to anti-malarial drug discovery.”
The presentation will be Wednesday Aug. 22, from 2:05-2:50 p.m. at the ACS’ 244th National Meeting & Exposition in Philadelphia at the Pennsylvania Convention Center. The oral presentation is scheduled during the Perspective in Applied Computational Methods session.
With more than 164,000 members, the ACS is the world’s largest scientific society and one of the world’s leading sources of authoritative scientific information. A nonprofit organization, chartered by Congress, ACS is at the forefront of the evolving worldwide chemical enterprise and the premier professional home for chemists, chemical engineers and related professions around the globe.
SCYNEXIS’ Kowalczyk will present sets of better practices for eight machine learning methods and the creation of a platform on which different compounds can be tested. It is the first truly reproducible research in the area of chemical informatics applied to drug discovery research, enabling the results to be easily verified.
The SCYNEXIS platform also eliminates the need to share proprietary intellectual property while advancing potential treatments for so-called neglected diseases like malaria by testing multiple compounds against the same platform.
SCYNEXIS has been involved for years in joint research for screening potential treatments for neglected diseases such as malaria and sleeping sickness.
The company has also developed a robust screening platform for the assessment of compounds against parasite species relevant to neglected tropical diseases. The platform was designed to identify compounds with potential activity in the areas of human and public health.
About SCYNEXIS
SCYNEXIS delivers innovative solutions to solve the toughest problems in drug discovery and development for our pharmaceutical, global health and life science partners. We have successfully delivered preclinical and clinical drug candidates to our customers across all major therapeutic indications and have developed a proprietary cyclophilin inhibitor pipeline for the treatment of a broad range of diseases, including HCV and inflammation. www.scynexis.com.
For further information, please contact:
SCYNEXIS Media Contact:
Rick Rountree
Rick Rountree Communications, Inc.
rick@rickrountree.com
Tel. +1 919-878-1144
Alissa Maupin
SCYNEXIS
Marketing & Communications Manager
Alissa.Maupin@scynexis.com
Tel. +1 919-206-7246
Paul J. Kowalczyk, Ph.D., senior computational chemist in the company’s Integrated Parasitology division, will make the presentation entitled, “Machine learning: Better practices applied to anti-malarial drug discovery.”
The presentation will be Wednesday Aug. 22, from 2:05-2:50 p.m. at the ACS’ 244th National Meeting & Exposition in Philadelphia at the Pennsylvania Convention Center. The oral presentation is scheduled during the Perspective in Applied Computational Methods session.
With more than 164,000 members, the ACS is the world’s largest scientific society and one of the world’s leading sources of authoritative scientific information. A nonprofit organization, chartered by Congress, ACS is at the forefront of the evolving worldwide chemical enterprise and the premier professional home for chemists, chemical engineers and related professions around the globe.
SCYNEXIS’ Kowalczyk will present sets of better practices for eight machine learning methods and the creation of a platform on which different compounds can be tested. It is the first truly reproducible research in the area of chemical informatics applied to drug discovery research, enabling the results to be easily verified.
The SCYNEXIS platform also eliminates the need to share proprietary intellectual property while advancing potential treatments for so-called neglected diseases like malaria by testing multiple compounds against the same platform.
SCYNEXIS has been involved for years in joint research for screening potential treatments for neglected diseases such as malaria and sleeping sickness.
The company has also developed a robust screening platform for the assessment of compounds against parasite species relevant to neglected tropical diseases. The platform was designed to identify compounds with potential activity in the areas of human and public health.
About SCYNEXIS
SCYNEXIS delivers innovative solutions to solve the toughest problems in drug discovery and development for our pharmaceutical, global health and life science partners. We have successfully delivered preclinical and clinical drug candidates to our customers across all major therapeutic indications and have developed a proprietary cyclophilin inhibitor pipeline for the treatment of a broad range of diseases, including HCV and inflammation. www.scynexis.com.
For further information, please contact:
SCYNEXIS Media Contact:
Rick Rountree
Rick Rountree Communications, Inc.
rick@rickrountree.com
Tel. +1 919-878-1144
Alissa Maupin
SCYNEXIS
Marketing & Communications Manager
Alissa.Maupin@scynexis.com
Tel. +1 919-206-7246
Subscribe to:
Comments (Atom)